Profile data is unavailable for this security.
About the company
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
- Revenue in USD (TTM)97.86m
- Net income in USD-45.69m
- Incorporated2020
- Employees179.00
- LocationRepare Therapeutics Inc7210 Frederick-Banting, Suite 100ST-LAURENT H4S 2A1CanadaCAN
- Websitehttps://www.reparerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 156.71m | 112.00 | -- | -- | -- | 7.13 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| CervoMed Inc | 9.49m | -593.84k | 156.90m | 8.00 | 9.63 | 21.98 | -- | 16.53 | 1.97 | 1.97 | 2.04 | 0.8648 | 0.719 | -- | -- | 1,186,515.00 | -4.50 | -53.67 | -5.49 | -58.89 | -- | -- | -6.26 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 157.77m | 28.00 | -- | 1.47 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 158.17m | 121.00 | -- | 0.8676 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Rezolute Inc | 0.00 | -58.21m | 158.53m | 51.00 | -- | 2.24 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 158.61m | 51.00 | -- | 0.6053 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 158.84m | 459.00 | -- | -- | -- | 1.54 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Syros Pharmaceuticals Inc | 6.98m | -144.49m | 160.37m | 68.00 | -- | 10.65 | -- | 22.97 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Alpha Tau Medical Ltd | 0.00 | -28.95m | 160.53m | 121.00 | -- | 2.03 | -- | -- | -0.4165 | -0.4165 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -26.50 | -- | -28.08 | -- | -- | -- | -- | -- | -- | -- | 0.0653 | -- | -- | -- | 13.64 | -- | -- | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 161.29m | 179.00 | -- | 0.6894 | -- | 1.65 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 161.67m | 158.00 | -- | 0.4709 | -- | 4.84 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 162.74m | 65.00 | -- | 1.57 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Galectin Therapeutics Inc | 0.00 | -44.78m | 162.83m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 162.85m | 1.00 | -- | 53.99 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 164.47m | 101.00 | -- | 8.86 | -- | 6.07 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 166.07m | 159.00 | -- | 4.08 | -- | 1.84 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
Data as of Jun 14 2024. Currency figures normalised to Repare Therapeutics Inc's reporting currency: US Dollar USD
47.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 10.33m | 24.35% |
| ARK Investment Management LLCas of 31 Mar 2024 | 2.70m | 6.37% |
| Deep Track Capital LPas of 31 Mar 2024 | 2.68m | 6.32% |
| Redmile Group LLCas of 31 Mar 2024 | 2.02m | 4.75% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 700.00k | 1.65% |
| Aquilo Capital Management LLCas of 31 Mar 2024 | 633.27k | 1.49% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 351.00k | 0.83% |
| Ensign Peak Advisors, Inc.as of 31 Mar 2024 | 344.33k | 0.81% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 308.45k | 0.73% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 260.75k | 0.61% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
